Mendelian randomization to evaluate the effect of folic acid supplement on the risk of Alzheimer disease

Medicine (Baltimore). 2024 Feb 9;103(6):e37021. doi: 10.1097/MD.0000000000037021.

Abstract

We conducted a study to evaluate the impact of folic acid supplementation on the risk of Alzheimer disease (AD). A Mendelian randomization (MR) analysis model assessed the causal effects of folic acid supplementation on AD, utilizing data from recent genome-wide association studies. Effect estimates were scrutinized using various methods: inverse-variance weighted (IVW), simple mode, weighted mode, simple median, weighted median, penalized weighted median, and the MR-Egger method. The sensitivity analysis assessed heterogeneity and pleiotropy of individual single nucleotide polymorphisms (SNPs) using the IVW method with Cochran Q statistics and MR Egger intercept, respectively. Additionally, a leave-one-out sensitivity analysis determined potential SNP-driven associations. Both fixed-effect and random-effect IVW models in the MR analysis revealed a reduced risk of AD associated with folic acid supplementation (odds ratio, 0.930; 95% CI, 0.903-0.958, P < .001; odds ratio, 0.930; 95% CI, 0.910-0.950, P < .001) based on 7 SNPs as instrumental variables. The reverse MR analysis indicated no causal association between AD and folic acid supplementation. This study, utilizing genetic data, suggests that folic acid supplementation may potentially reduce the risk of AD and provides novel insights into its etiology and preventive measures.

MeSH terms

  • Alzheimer Disease* / epidemiology
  • Alzheimer Disease* / genetics
  • Alzheimer Disease* / prevention & control
  • Dietary Supplements
  • Folic Acid* / therapeutic use
  • Genome-Wide Association Study
  • Humans
  • Mendelian Randomization Analysis

Substances

  • Folic Acid